Erythropoietin beim multiplen Myelom

M Pecherstorfer, F Schmoranzer, M Vesely, A Fortelny, G Baumgartner

Publikation: Beitrag in Fachzeitschrift (peer-reviewed)Artikel in Fachzeitschrift

5 Zitate (Scopus)

Abstract

In a 59-year-old man with multiple myeloma (kappa-light chain paraproteinaemia) in stage IIIB, bone marrow infiltration with atypical plasma cells was reduced by five cytostatic treatment courses with vincristine, melphalan, cyclophosphamide and prednisone (VMCP protocol), but anaemia requiring blood transfusion persisted (haemoglobin concentration 5.3 g/dl). Even administration of interferon alpha-2b (5 million units s.c. every other day) failed to alter this. Only a combination of interferon and erythropoietin (150 U/kg i.v. every other day) achieved lasting regression of the anaemia (haemoglobin concentration up to 14 g/dl). In four other anaemic patients with multiple myeloma, stage III, treated according to the VMCP protocol but without additional interferon, erythropoietin did not improve erythropoiesis.

Titel in ÜbersetzungErythropoietin in multiple myeloma
OriginalspracheDeutsch
Seiten (von - bis)1096-9
Seitenumfang4
FachzeitschriftDeutsche Medizinische Wochenschrift
Jahrgang115
Ausgabenummer28-29
DOIs
PublikationsstatusVeröffentlicht - 13 Juli 1990
Extern publiziertJa

Schlagwörter

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Bone Marrow/pathology
  • Cyclophosphamide/administration & dosage
  • Erythropoiesis
  • Erythropoietin/administration & dosage
  • Female
  • Humans
  • Interferon alpha-2
  • Interferon-alpha/administration & dosage
  • Male
  • Melphalan/administration & dosage
  • Middle Aged
  • Multiple Myeloma/drug therapy
  • Prednisone/administration & dosage
  • Recombinant Proteins
  • Vincristine/administration & dosage

Fingerprint

Untersuchen Sie die Forschungsthemen von „Erythropoietin beim multiplen Myelom“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren